Animesh Pardanani - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Animesh Pardanani's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Animesh Pardanani
Verified
Contributor, Freelance
Beats
Chronic Illness, Chronic Pain illness, FND Functional Neurological Disorder,Autism Family
Haven't found such a thing yet.
Content
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases
By Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi| Wiley Online Library Verified To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.
By Ayalew Tefferi, Animesh Pardanani, Naseema Gangat Verified| Wiley Online Library Verified EDITORIAL Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? Ayalew Tefferi, Corresponding Author Ayalew Tefferi Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA Correspondence Ayalew Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases
By Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi| Wiley Online Library Verified To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.
Company Info
Freelance
Freelancer.com is the largest freelancing and crowdsourcing marketplace in the world, connecting over 81 million employers and freelancers across more than 247 countries. Founded in 2009 and based in Sydney, Australia, the platform allows employers to post jobs while freelancers can bid on these projects. It is publicly traded on the Australian Securities Exchange under the ticker ASX:FLN. The platform supports a variety of work categories, including software development, writing, design, and marketing. Freelancer.com also offers contests for creative work, where employers can award prize money to winning entries. Users can choose from different membership plans, including free and paid subscriptions, which provide various benefits. The mobile app enhances project management and communication for users on the go. With a diverse customer base that includes individuals, small businesses, and large enterprises, Freelancer.com plays a significant role in the global online economy.
De Pere, Wisconsin, United States